Please try another search
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; and Salinomycin, an anti-coccidial feed additive for chickens. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; KP-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis; KP-910, which is in phase I clinical trial for peripheral neuropathic pain; Seladelpar that is in phase I clinical trial for primary biliary cholangitis; and Tildacerfont, which is in phase I clinical trial for congenital adrenal hyperplasia. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Kazumori Ishiguro | - | 2022 | Standing Audit & Supervisory Board Member |
Kiyoko Kamibeppu | - | 2019 | Independent Outside Director |
Yoshio Tanabe | - | 2016 | Director |
Yasutomo Inoue | 63 | 2021 | Independent Outside Director |
Hiroaki Matsumoto | 65 | 2021 | Outside Audit & Supervisory Board Member |
Masashi Suzudo | 61 | 2020 | GM of Corporate Planning & Coordination Department and Director |
Naomi Doi | - | 2018 | Standing Audit & Supervisory Board Member |
Hiroyuki Horiuchi | - | 2016 | President & Representative Director |
Hirotoshi Endo | - | 2019 | Outside Audit & Supervisory Board Member |
Masahiro Matsuura | 54 | 2020 | Director |
Shoichiro Takagi | - | 2020 | Independent Outside Director |
Minoru Ohta | - | 2020 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review